MedTrace Logo

Physician Assessment of the Clinical Utility of a Patient-Specific 3D Electro-Anatomical Heart Model in VT Ablation

NCT04841382 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2022-10-19

No results posted yet for this study

Summary

ACE-VT is a clinical pilot study designed to evaluate the ability of the CardioSolv Software System to generate an output for the physician to review in a timely fashion, consistent with the standard of care VT ablation workflow. This study will assess the acute effectiveness of using the CardioSolv Software System output as additional supporting information during ablation.

Conditions

  • Ischemic Monomorphic Ventricular Tachycardia

Interventions

OTHER

Supporting information.

CardioSolv Software System is a software-based medical device meant which creates a patient-specific 3D heart model that provides physiologic information.

Sponsors & Collaborators

  • CardioSolv Ablation Technologies

    lead INDUSTRY

Principal Investigators

  • Saman Nazarian, MD · University of Pennsylvania

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2022-10-06
Completion
2022-10-06

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04841382 on ClinicalTrials.gov